Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 8/20 | 0.77 |
| ▸ | MPC2 | O95563 | 2/20 | 0.77 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.77 |
| ▸ | FFAR1 | O14842 | 11/20 | 0.55 |
| ▸ | PPARA | Q07869 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19217766 | 0.88 | PPARG (0.79) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL29376450 | 0.87 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL18541511 | 0.87 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL18541485 | 0.87 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL623654 | 0.87 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL935850 | 0.87 | PPARG (0.77) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6928170 | 0.87 | PPARG (0.79) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL19828831 | 0.87 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL18541499 | 0.87 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL935826 | 0.87 | PPARG (1.00) | PPARGMPC2CYP2C8CYP2C9FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | CIRIUS THERAPEUTICS, INC. | 2010-09-02 | — | — | US | claimed |
| EP-2203433-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | Metabolic Solutions Development Company (US) | 2010-07-07 | — | — | EP | claimed |
| WO-2009038681-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2009-03-26 | — | — | WO | claimed |
| US-20230210825-A1 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS | CIRIUS THERAPEUTICS, INC. | 2023-07-06 | — | — | US | disclosed |
| US-20230013627-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2023-01-19 | — | — | US | disclosed |
| US-20220031667-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2022-02-03 | — | — | US | disclosed |
| US-20210361629-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. | 2021-11-25 | — | — | US | disclosed |
| WO-2021212054-A1 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS | CIRIUS THERAPEUTICS, INC. (US) | 2021-10-21 | — | — | WO | disclosed |
| WO-2020146810-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | CIRIUS THERAPEUTICS, INC. (US) | 2020-07-16 | — | — | WO | disclosed |
| EP-3202401-B1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CIRIUS THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| EP-3202401-B1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | CIRIUS THERAPEUTICS INC (US) | 2019-10-23 | — | — | EP | disclosed |
| WO-2011075514-A1 | PPAR-SPARING THIAZOLIDINEDIONES AND COMBINATIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-06-23 | — | — | WO | disclosed |
| WO-2010105048-A9 | THIAZOLIDINEDIONE ANALOGUES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2011-01-27 | — | — | WO | disclosed |
| WO-2010105048-A1 | THIAZOLIDINEDIONE ANALOGUES | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | CIRIUS THERAPEUTICS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | CIRIUS THERAPEUTICS, INC. | 2010-09-02 | — | — | US | disclosed |
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | CIRIUS THERAPEUTICS, INC. | 2010-09-02 | — | — | US | disclosed |
| EP-2203433-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | Metabolic Solutions Development Company (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2009038681-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009038681-A1 | THIAZOLIDINEDIONE ANALOGUES FOR THE TREATMENT OF HYPERTENSION | METABOLIC SOLUTIONS DEVELOPMENT COMPANY (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222399-A1 | Thiazolidinedione Analogues For The Treatment Of Hypertension | AGTR2, ADRB1, ADRB3 | PPARG 42/4885MPC2 989/4885CYP2C8 850/4885 |
| US-20230210825-A1 | METHODS AND COMPOSITIONS FOR TREATING SUBJECTS WITH METABOLIC DISORDERS AND CORONAVIRUS INFECTIONS | ACE, DPP4, ACE2 | PPARG 19/4885MPC2 223/4885CYP2C8 548/4885 |
| US-20210361629-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | PPARD, FABP1, GOT2 | PPARG 4/4885MPC2 194/4885CYP2C8 361/4885 |
| US-20230013627-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | FABP1, HNF4A, PPARD | PPARG 6/4885MPC2 153/4885CYP2C8 524/4885 |
| US-20220031667-A1 | THIAZOLIDINEDIONE ANALOGS FOR THE TREATMENT OF NAFLD AND METABOLIC DISEASES | PPARD, FABP1, GOT2 | PPARG 4/4885MPC2 194/4885CYP2C8 361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.